← Back to graph
Prescription

paricalcitol

Selected indexed studies

  • Paricalcitol and Extended-Release Calcifediol for Treatment of Secondary Hyperparathyroidism in Non-Dialysis Chronic Kidney Disease: Results From a Network Meta-Analysis. (J Clin Endocrinol Metab, 2023) [PMID:37235771]
  • Paricalcitol plus hydroxychloroquine enhances gemcitabine activity and induces mesenchymal to epithelial transition in pancreatic ductal adenocarcinoma: A single cell RNA-seq analysis. (Cancer Lett, 2025) [PMID:40409452]
  • Paricalcitol ameliorates diabetic nephropathy by promoting EETs and M2 macrophage polarization and inhibiting inflammation by regulating VDR/CYP2J2 axis. (FASEB J, 2024) [PMID:39441644]

_Worker-drafted node — pending editorial review._

Connections

No connections recorded yet.

Sources

Local graph